When Merck & Co. pulled Vioxx from pharmacy shelves worldwide on 30 September 2004, chief executive Raymond Gilmartin framed it as a responsible company acting on new data; the documented record shows a five-year gap between that posture and what the company’s own clinicians had measured. Vioxx (rofecoxib), a COX-2 selective anti-inflammatory approved by the U.S. Food and Drug Administration on 20 May 1999 and marketed as a gentler painkiller that spared the stomach, was instead associated with one of the largest drug-safety catastrophes in regulatory history. FDA drug-safety reviewer David Graham would testify to the Senate Finance Committee on 18 November 2004 that the drug had caused on the order of 88,000 to 139,000 excess heart attacks and strokes in the United States, of which perhaps 30 to 40 percent were fatal — a toll he compared to between two and four jumbo-jet crashes a week sustained over five years.
The gap between promise and reality was not discovered late; it was visible in Merck’s own trials. The VIGOR study, published in The New England Journal of Medicine on 23 November 2000 under lead author Claire Bombardier, showed that the 8,076 patients taking rofecoxib had roughly four to five times the rate of myocardial infarction of patients taking the older drug naproxen — a relative risk the published paper reported as 0.2 in naproxen’s favor. Merck attributed the difference to a supposed protective effect of naproxen rather than a cardiac hazard of Vioxx — a hypothesis that was never proven and that the company continued to advance while sales climbed past $2.5 billion a year and a sales force of more than 3,000 representatives carried the message to prescribers.
The withdrawal came only when the harm became impossible to explain away. The APPROVe trial — designed to test whether Vioxx prevented recurrent colon polyps, not to study the heart — was halted early on 23 September 2004 after showing that rofecoxib roughly doubled the risk of confirmed cardiovascular events after eighteen months of use, against placebo. The verdict here is therefore plain at the outset: an approved, heavily advertised, trusted medicine reached tens of millions of patients while the signal that would eventually condemn it sat in the company’s data, the FDA’s review files, and the medical literature, fully legible to anyone with access and the will to read it.
What followed was the largest pharmaceutical mass-tort reckoning of its era. In November 2007 Merck agreed to pay $4.85 billion to resolve roughly 27,000 lawsuits covering some 47,000 plaintiff groups, NEJM issued a formal “Expression of Concern” alleging the VIGOR authors had withheld cardiac data, and the case became the standard byword for how surrogate-endpoint approval, aggressive marketing, and suppressed safety signals can converge into mass harm before any regulator pulls the cord.
When the U.S. Food and Drug Administration asked manufacturers to pull propoxyphene from the American market on 19 November 2010, it was retiring a painkiller that Eli Lilly had introduced in 1957 and that had been prescribed to tens of millions of people across two regulatory generations; the documented record shows the agency acted only after a study it had itself ordered proved the harm, and decades after the first petition to ban the drug was filed. Propoxyphene — marketed alone as Darvon and combined with acetaminophen as Darvocet — was promoted for half a century as a mild, well-tolerated opioid for moderate pain. The gap between that gentle reputation and the molecule’s actual pharmacology was the whole story: at or near ordinary therapeutic doses the drug prolonged the PR interval, widened the QRS complex, and lengthened the QT interval, the electrocardiographic signature of a compound that can stop a heart.
The harm was not subtle and not new. Propoxyphene blocks cardiac sodium channels more potently than the antiarrhythmic agents lidocaine, quinidine, and procainamide, and its long-lived metabolite norpropoxyphene accumulates — especially in the elderly and in patients with impaired kidneys — pushing toxic effects past the point of reversal. The consumer group Public Citizen petitioned the FDA to ban propoxyphene in 1978 and again in February 2006. The drug had been associated with more than 2,000 accidental U.S. deaths since 1981 and ranked among the most common drugs found in fatal overdoses, a mortality profile that prompted the United Kingdom to begin withdrawing the equivalent product, co-proxamol, in January 2005.
The verdict here is therefore plain at the outset: an approved, familiar, “weak” medicine reached enormous populations while the evidence that would eventually condemn it — sodium-channel data, autopsy series, decades of overdose statistics, and a foreign regulator’s reversal — sat fully legible in the literature. The thing that finally moved the FDA was not new theory but a single dedicated experiment: a controlled electrocardiographic study in healthy volunteers, completed in 2010, showing that even at labeled doses propoxyphene measurably deranged cardiac conduction.
What followed the withdrawal was less a courtroom reckoning than a public-health correction visible in the morgue. In the state of Florida, where overdose deaths are tracked closely, fatalities involving propoxyphene fell on the order of 84 percent after the drug left the market — a natural experiment that quantified, in lives, the cost of every year the agency had waited. Propoxyphene became the standard byword for regulatory delay: a case in which the question was not whether a drug was dangerous but how long an agency could decline to answer a petition it had already received twice.
When Wyeth-Ayerst Laboratories pulled Duract from American pharmacies on 22 June 1998, the company cast it as a precaution against rare liver events in patients who had overstayed a clearly printed 10-day limit; the documented record shows the hepatic hazard was visible inside the drug’s own approval file nearly a year earlier, and that an FDA medical officer had argued — and lost — for a boxed warning before a single prescription was written. Duract (bromfenac sodium), a short-term non-steroidal anti-inflammatory approved by the U.S. Food and Drug Administration on 15 July 1997 for acute pain lasting ten days or less, instead became one of the fastest market withdrawals of the modern era. In roughly eleven months it generated some 2.5 million prescriptions and was associated with at least four deaths and eight liver transplants from fulminant hepatic failure, plus a further dozen serious liver injuries, with the count of severe drug-induced liver injury cases ultimately climbing past fifty.
The gap between promise and harm was not a post-market surprise. Bromfenac’s submission already showed that roughly 15 percent of short-term trial patients developed elevations of the liver enzymes AST or ALT to three times the upper limit of normal — a signal of hepatocellular stress markedly greater than that seen with comparable NSAIDs. The FDA medical reviewer who read that data advocated a black-box warning as a condition of approval and was overruled; the drug shipped instead with a routine label and a duration cap of ten days, on the theory that limiting exposure would contain the risk.
That theory collapsed against ordinary prescribing behavior. Acute pain frequently does not resolve in ten days, refills were written, and patients took bromfenac for weeks. The cases that killed and transplanted clustered almost entirely in this extended-use population — the precise scenario the 10-day rule was meant to prevent but had no mechanism to enforce. The verdict here is therefore plain at the outset: an approved, branded analgesic reached millions while the hepatotoxic signal that would condemn it sat fully legible in the agency’s own pre-approval review.
What followed was a rapid, near-total revocation. Wyeth strengthened the warnings in February 1998, the harm continued, and the company withdrew the drug in June; the FDA later formally rescinded the New Drug Application. The molecule survived only by abandoning the bloodstream — reformulated years later as a topical eye drop, where systemic exposure was negligible — while “Duract” became a byword for a withdrawal whose justification had been written before the launch.